Hypercholesterolemia or hypertriglyceridemia have been reported with the mTOR inhibitors [40,44,45], and one group of investigators recommends treating this adverse event with statins in patients continuing on long-term temsirolimus treatment [41]. This evidence concerns the gene MTOR and familial hypercholesterolemia.